HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT06963580

MI078 Capsule for depression

This study is completed in China. It is testing MI078 Capsule for depression.

DepressionDrugFrom 18 Years to 45 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of placebo for people with depression.

Who could participate?

This study is for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria apply.

Listed locations
Wuhu, China · Beijing, China and 16 more locationsSee all locations and recruitmentA listed location does not confirm current availability.

Compensation and expense reimbursement have not been verified for this summary.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: September 9, 2024
Recruitment status
Completed
Enrollment listed in the registry
72
Sponsor
Nanjing Minova Pharmaceutical Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
China
Age range
From 18 Years to 45 Years
Official registry ID
NCT06963580
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MI078 Capsule in Patients With Postpartum Depression

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT06963580. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Wuhu · Beijing · Xiamen

15 more locations
  • Foshan
  • Guangzhou
  • Nanning
  • Guiyang
  • Shijiazhuang
  • Xingtai
  • Nanchang
  • Shanghai
  • Linfen
  • Taiyuan
  • Chengdu
  • Kunming
  • Hangzhou
  • Ningbo
  • Wenzhou
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of placebo for people with depression.

Who is behind this study?

The study sponsor is Nanjing Minova Pharmaceutical Co., Ltd., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including MI078 capsule dose 1, MI078 capsule dose 2 and placebo.

Who can participate?

This study is for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.